Company
Standardized culture and objective readout, so organoid data can stand in for animal tests
Who we are
AiderBio is a Korean biotech start-up founded in 2025. We develop two products that work together: OrganoKit, a 3D organoid culture kit with our patent-pending Port Pocket structure, and AI software that predicts drug toxicity from organoid images.
Our team brings together 3D cell culture, biomaterials, pharmacology and image analysis. We work with an ophthalmology clinic, a national veterans hospital and a national university hospital to build disease models from patient-derived cells.
Mission
Make non-animal drug testing reproducible across labs and operators.
Focus
Start with ophthalmology, then extend to multi-organ organoid pipelines.
Principle
Build on patient-derived cells and clinical partners, so results hold up in people.
Company Overview
| Company | AiderBio Co., Ltd. |
|---|---|
| CEO | Dongwoo Kim, Ph.D. |
| Founded | September 2, 2025 |
| Business | 3D organoid and spheroid culture kits, AI toxicity analysis software and services, disease model research |
| Headquarters | 2F 201-30, 27-3 Iksan-daero 2-gil, Iksan-si, Jeonbuk State, Republic of Korea |
| R&D Center | Veterans Medical Research Institute, VHS Medical Center, Seoul |
| Certification | Certified corporate R&D department (KOITA) |
| qaz8949@aiderbio.com |